A Comparison of Leuprolide with Flutamide and Leuprolide in Previously Untreated Patients with Clinical Stage D2 Cancer of the Prostate

Economic evaluations in NCI-sponsored network cancer clinical trials

VT Nghiem;R Vaidya;GH Lyman;DL Hershman;SD Ramsey;JM Unger Value in Health Dec;23(12):1653-1661. doi: 10.1016/j.jval.2020.08.2095. Epub 2020 Oct 9

PMid: PMID33248521 | PMC number: PMC8262264

Association of Patient Demographic Characteristics and Insurance Status with Survival in Cancer Randomized Clinical Trials with Positive Findings

JM Unger;CD Blanke;M Leblanc;W Barlow;R Vaidya;M Fleury;SD Ramsey;DL Hershman JAMA Network Open Apr 1;3(4):e203842

PMid: PMID32352530 | PMC number: PMC7193331

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 & S9346)

C Tangen;M Hussain;C Higano;M Eisenberger;E Small;G Wilding;B Donnelly;PM Venner;P Schellhammer;ED Crawford;N Vogelzang;I Powell;IM Thompson Journal of Urology 188(4):1164-1169;

PMid: PMID22921015 | PMC number: PMC3481164

Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328

KS Albain;JM Unger;JJ Crowley;CA Coltman;DL Hershman Journal of the National Cancer Institute 101(14):984-992

Cooperative group trials - Southwest Oncology Group (SWOG) innovations in advanced prostate cancer [PMID21085622; PMC2981166]

TB Dorff;C Tangen;ED Crawford;DP Petrylak;CS Higano;D Raghavan;DI Quinn;NJ Vogelzang;IM Thompson;MHA Hussain Therapeutic Advances in Medical Oncology 1(2):69-77;

Minority report: how best to analyze clinical trial data to address disparities

D Hershman;J Unger Breast Cancer Research and Treatment 118:519-521

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Overview analysis issues using combined androgen deprivation overview analysis as an example.

BA Blumenstein Urologic Oncology 1:95-100

Prognostic factors in stage D2 prostate cancer; important implications for future trials: Results of a cooperative intergroup study (INT.0036).

MA Eisenberger;ED Crawford;M Wolf;B Blumenstein;DG McLeod;R Benson;FA Dorr;M Benson;JT Spaulding Seminars in Oncology 21(5):613-619

Some statistical considerations for the interpretation of trials of combined androgen therapy.

BA Blumenstein Cancer Supplement 72(12):3834-3840

The use of flutamide in hormone-refractory metastatic prostate cancer.

DG McLeod;RC Benson, Jr;MA Eisenberger;ED Crawford;BA Blumenstein;D Spicer;JT Spaulding Cancer Supplement 72(12):3870-3873

A comparison of leuprolide and flutamide vs leuprolide alone in newly diagnosed stage D2 prostate cancer: Prognostic and therapeutic importance of the minimal disease subset.

M Eisenberger;ED Crawford;D McLeod;R Benson;A Dorr;B Blumenstein ASCO 11:201(#619)

Evaluation of "complete androgen blockade" (CAB) with flutamide (F) added to leuprolide (L) after progression on leuprolide (L) alone: Results of INT-0036 study in stage D2 cancer of the prostate (CP).

D McLeod;B Blumenstein;M Eisenberger;ED Crawford;D Spicer;J Spaulding;A Dorr;R Benson ASCO 9:136(#526)

Combined androgen blockade: Leuprolide and flutamide versus leuprolide and placebo.

ED Crawford;P Goodman;B Blumenstein Seminars in Urology 8(3):154-158

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

ED Crawford;MA Eisenberger;DG McLeod;JT Spaulding;R Benson;FA Dorr;BA Blumenstein;MA Davis;PJ Goodman N Engl J Med 321:419-424

Significance of pre-treatment stratification by extent of disease(ED) in stage D2 prostate cancer (PC) patients treated with leuprolide +flutamide (LF) or leuprolide + placebo (LP).

M Eisenberger;ED Crawford;B Blumenstein;R Benson;D McLeod;A Dorr;J Spaulding ASCO 8:132(#515)

Treatment of newly diagnosed stage D2 prostate cancer withleuprolide and flutamide or leuprolide alone, phase III, intergroupstudy 0036.

JE Mortimer;J Chestnut;CS Higano;G Goodman ASCO 7:119(#460)